Prior notification of a concentration

(Case M.9426 — 3M Company/Acelity)

(Text with EEA relevance)

(2019/C 308/06)

1. On 3 September 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1].

This notification concerns the following undertakings:

— 3M Company ('3M', US),

— Acelity, Inc. ('Acelity', US).

3M acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Acelity.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— 3M is a diversified technology company. Through its health care division, 3M offers a broad range of medical solutions, including advanced wound dressings,

— Acelity is primarily active in the development and commercialisation of advanced wound care products, including through its subsidiaries Kinetic Concepts, Inc, Systagenix Wound Management, Limited and Crawford Healthcare Limited.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9426 — 3M Company/Acelity

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').